India’s First ‘Smart’ Brain Implant: Aster Medcity Launches Adaptive DBS for Advanced Parkinson’s

KOCHI, INDIA — In a landmark development for Neuromodulation in South Asia, Aster Medcity Kochi announced the launch of India’s first clinical application of Adaptive Deep Brain Stimulation (aDBS) on March 28, 2026. This “smart” technology represents a paradigm shift in treating advanced Parkinson’s disease, moving away from the “one-size-fits-all” approach of constant electrical stimulation toward a responsive system that adjusts to a patient’s internal brain signals in real-time.

The introduction of the Medtronic Percept™ PC system with BrainSense™ technology at Aster’s Parkinson and Movement Disorders Centre marks the first time this FDA-approved adaptive software has been deployed for patient care in the Indian clinical circuit. For the millions of Indians living with Parkinson’s—many of whom develop the condition a decade earlier than their Western counterparts—this innovation offers a more personalized, automated path to motor control.

Beyond the “Brain Pacemaker”: How Adaptive DBS Works

Traditional Deep Brain Stimulation (DBS) has often been compared to a cardiac pacemaker. Surgeons implant thin wires into specific regions of the brain—most commonly the subthalamic nucleus—which deliver a continuous stream of electricity to block the erratic signals causing tremors, rigidity, and bradykinesia (slowness of movement).

While effective, traditional DBS is “fixed.” If a patient is resting, they receive the same level of stimulation as when they are trying to walk or eat. This can lead to over-stimulation, causing side effects like involuntary writhing movements (dyskinesia), or under-stimulation during periods of high stress or medication “off-times.”

Adaptive DBS (aDBS) functions more like a “brain thermostat.” It utilizes sensing technology to monitor beta-band oscillations, which are specific neural biomarkers associated with Parkinson’s symptoms.

• Real-time Adjustment: When the device detects high levels of these biomarkers, it automatically increases stimulation.

• Rest and Recovery: When the brain signals stabilize, the device scales back.

• Efficiency: Research suggests this “on-demand” approach can reduce total stimulation by up to 50%, potentially doubling the battery life of the implanted device.

Expert Insights: A New Era of Personalized Care

Dr. Asha Kishore, Director of the Parkinson and Movement Disorders Centre at Aster Kerala Cluster, emphasized that this technology addresses the most frustrating aspect of advanced Parkinson’s: unpredictability.

“This highly personalized approach ensures that patients receive the exact amount of therapy they need at any given moment without having to make manual adjustments,” said Dr. Kishore, who brings over 35 years of expertise in movement disorders to the program. “The new sensing-enabled system allows us to track signals in the brain even while the patient is at home, making the treatment truly data-driven.”

Medical professionals not involved in the Aster launch have also noted the systemic benefits. Dr. Guruprasad Hosurkar, a neurologist at KIMS Hospitals—which has also explored similar sensing technologies—noted that lowering unnecessary stimulation exposure is a critical step in reducing long-term side effects like speech impairment (dysarthria) or balance issues (disequilibrium).

Clinical Evidence: Better “On-Time” with Fewer Side Effects

The transition to adaptive systems is backed by robust multinational data. According to a pilot study published in Parkinson’s News Today, aDBS outperformed standard DBS in increasing the “on-time” for patients—the periods during the day when symptoms are well-controlled without bothersome involuntary movements.

Key findings from chronic trials include:

• Reduced Dyskinesia: Because the device scales back when stimulation isn’t needed, patients experience fewer medication-induced involuntary movements.

• Stability: Clinical data involving patients over eight-month periods showed that neural signals remained stable, allowing for consistent therapy.

• Quality of Life: In a case study of a 62-year-old male patient, researchers observed significant motor gains and a marked reduction in daily medication reliance within three months of activating the adaptive settings.

The Indian Context: A Growing Public Health Challenge

The timing of this launch is critical. India is currently facing a surge in Parkinson’s cases, with prevalence estimated between 15 to 43 per 100,000 people. Concerningly, Indian patients often show an earlier onset; while the global average age of diagnosis is in the 60s, nearly 40-45% of Indian cases occur between the ages of 22 and 49.

For a younger workforce, the disability associated with Parkinson’s isn’t just a health issue—it is an economic one. “Young-onset Parkinson’s disrupts the most productive years of a person’s life,” Dr. Kishore noted. By providing a system that requires fewer manual tweaks and clinic visits, aDBS empowers patients to maintain independence and remain in the workforce longer.

Balancing the Promise: Limitations and Risks

While aDBS is a significant leap forward, it is not a “cure,” nor is it suitable for every patient. As with any neurosurgical procedure, there are inherent risks that both clinicians and patients must weigh:

1. Surgical Risks: Although rare in high-volume centers, there is a 1-3% risk of intracranial hemorrhage, as well as risks of infection or seizures.

2. Technological Barriers: The success of aDBS depends on the device’s ability to identify a clear “biomarker” in the patient’s brain. In some patients, these signals may be too weak to guide the adaptive software effectively.

3. Cost and Access: While the extended battery life offers long-term savings, the initial cost of “smart” DBS systems remains high, potentially limiting access for patients in resource-poor regions.

4. Specialized Programming: aDBS requires a high level of expertise from the neurology team to program the initial parameters.

Practical Implications for Patients

For patients currently managing advanced Parkinson’s with fluctuating medication responses, aDBS represents a new tier of intervention. Experts suggest that the ideal candidates are those who have seen success with Levodopa but find the “window” of effectiveness narrowing, leading to frequent “off” periods or dyskinesia.

As India moves toward becoming a global hub for medical tourism and advanced neuromodulation, the launch at Aster Medcity signals a future where “precision medicine” is no longer a buzzword, but a standard of care for neurological disorders.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.